[go: up one dir, main page]

WO2013033271A3 - Méthode permettant d'améliorer le système immunitaire en réaction à une maladie ou une lésion - Google Patents

Méthode permettant d'améliorer le système immunitaire en réaction à une maladie ou une lésion Download PDF

Info

Publication number
WO2013033271A3
WO2013033271A3 PCT/US2012/052944 US2012052944W WO2013033271A3 WO 2013033271 A3 WO2013033271 A3 WO 2013033271A3 US 2012052944 W US2012052944 W US 2012052944W WO 2013033271 A3 WO2013033271 A3 WO 2013033271A3
Authority
WO
WIPO (PCT)
Prior art keywords
insult
injury
disease
response
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/052944
Other languages
English (en)
Other versions
WO2013033271A2 (fr
Inventor
Derren Barken
Israel Barken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013033271A2 publication Critical patent/WO2013033271A2/fr
Publication of WO2013033271A3 publication Critical patent/WO2013033271A3/fr
Priority to US13/970,537 priority Critical patent/US20140065629A1/en
Priority to US13/971,847 priority patent/US20140065098A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un exemple de la présente invention porte sur une agression délibérée ou sur la reconnaissance qu'une agression s'est produite chez un patient, ladite agression induisant un événement de reconnaissance par le système immunitaire. Le répertoire des lymphocytes T est catalogué à partir d'échantillons des lymphocytes du patient avant et après l'agression afin de détecter et de séquencer les loci TCR alpha et bêta de clonotypes de lymphocytes T fortement développés. Dans certains exemples, cette information est utilisée à son tour pour générer des lymphocytes T autologues ou pour créer des lymphocytes T génétiquement modifiés autologues, les deux types comprenant des séquences TCR qui ciblent la maladie ou la lésion de l'individu, et soignent ou améliorent ainsi les symptômes.
PCT/US2012/052944 2011-08-29 2012-08-29 Méthode permettant d'améliorer le système immunitaire en réaction à une maladie ou une lésion Ceased WO2013033271A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/970,537 US20140065629A1 (en) 2012-08-29 2013-08-19 Methods of treating diseases
US13/971,847 US20140065098A1 (en) 2012-08-29 2013-08-21 Method to augment immune system in response to disease or injury

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528657P 2011-08-29 2011-08-29
US61/528,657 2011-08-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/970,537 Continuation-In-Part US20140065629A1 (en) 2012-08-29 2013-08-19 Methods of treating diseases
US13/971,847 Continuation-In-Part US20140065098A1 (en) 2012-08-29 2013-08-21 Method to augment immune system in response to disease or injury

Publications (2)

Publication Number Publication Date
WO2013033271A2 WO2013033271A2 (fr) 2013-03-07
WO2013033271A3 true WO2013033271A3 (fr) 2013-05-10

Family

ID=47757162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/052944 Ceased WO2013033271A2 (fr) 2011-08-29 2012-08-29 Méthode permettant d'améliorer le système immunitaire en réaction à une maladie ou une lésion

Country Status (1)

Country Link
WO (1) WO2013033271A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
DK3511423T4 (da) 2012-10-17 2024-07-29 Spatial Transcriptomics Ab Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve
US20140356318A1 (en) * 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
US9868979B2 (en) 2013-06-25 2018-01-16 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
WO2016162309A1 (fr) 2015-04-10 2016-10-13 Spatial Transcriptomics Ab Analyse de plusieurs acides nucléiques spatialement différenciés de spécimens biologiques
MA49352A (fr) 2017-05-26 2020-04-08 Abvitro Llc Séquençage de bibliothèque de polynucléotides à haut rendement et analyse de transcriptome
MA50079A (fr) * 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
EP3976820A1 (fr) 2019-05-30 2022-04-06 10X Genomics, Inc. Procédés de détection de l'hétérogénéité spatiale d'un échantillon biologique
WO2021247543A2 (fr) 2020-06-02 2021-12-09 10X Genomics, Inc. Procédés de banques d'acides nucléiques
EP4600376A3 (fr) 2020-06-02 2025-10-22 10X Genomics, Inc. Transcriptome spatial pour récepteurs d'antigènes
EP4421186B1 (fr) 2020-06-08 2025-08-13 10X Genomics, Inc. Procédés de détermination d'une marge chirurgicale et procédés d'utilisation de ceux-ci

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085816A (ko) * 1998-09-17 2001-09-07 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
WO2006083969A2 (fr) * 2005-02-01 2006-08-10 Amnis Corporation Analyse sanguine et cellulaire au moyen d'un cytometre en flux imageur
US20070117134A1 (en) * 2005-11-18 2007-05-24 Kou Zhong C Method for detection and quantification of T-cell receptor Vbeta repertoire
US20110207134A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Monitoring health and disease status using clonotype profiles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010085816A (ko) * 1998-09-17 2001-09-07 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
WO2006083969A2 (fr) * 2005-02-01 2006-08-10 Amnis Corporation Analyse sanguine et cellulaire au moyen d'un cytometre en flux imageur
US20070117134A1 (en) * 2005-11-18 2007-05-24 Kou Zhong C Method for detection and quantification of T-cell receptor Vbeta repertoire
US20110207134A1 (en) * 2008-11-07 2011-08-25 Sequenta, Inc. Monitoring health and disease status using clonotype profiles

Also Published As

Publication number Publication date
WO2013033271A2 (fr) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2013033271A3 (fr) Méthode permettant d'améliorer le système immunitaire en réaction à une maladie ou une lésion
Gammazza et al. Human molecular chaperones share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19
Nguyen et al. Origins of CD 4+ circulating and tissue‐resident memory T‐cells
Kalekar et al. Relationship between CD4 regulatory T cells and anergy in vivo
Purcell et al. Immunity to fish rhabdoviruses
Wu et al. Immune tolerance of embryo implantation and pregnancy: the role of human decidual stromal cell-and embryonic-derived extracellular vesicles
WO2012129507A8 (fr) Système d'aide de santé et comportementale analytique adaptative et procédé d'utilisation associé
Sampath et al. Newly identified T cell subsets in mechanistic studies of food immunotherapy
Elfeki et al. Graft‐versus‐host disease after orthotopic liver transplantation: multivariate analysis of risk factors
WO2014005040A3 (fr) Flux de travaux automatisé de feuille de données cliniques
Fagone et al. VGX‐1027 modulates genes involved in lipopolysaccharide‐induced T oll‐like receptor 4 activation and in a murine model of systemic lupus erythematosus
Beumer-Chuwonpad et al. The potential of tissue-resident memory T cells for adoptive immunotherapy against cancer
Araujo Furlan et al. Limited Foxp3+ regulatory T cells response during acute Trypanosoma cruzi infection is required to allow the emergence of robust parasite-specific CD8+ T cell immunity
Al Madhoun et al. Comparative proteomic analysis identifies EphA2 as a specific cell surface marker for Wharton’s jelly-derived mesenchymal stem cells
Morris Cell formation by myxozoan species is not explained by dogma
Massoud et al. Immunology of aging
Kaufmann T-Cell paradigms in parasitic and bacterial infections
Van Kaer Comeback kids: CD8+ suppressor T cells are back in the game
Kawashima et al. Sensorless nonlinear control for a miniature pneumatic curling rubber actuator using robust right coprime factorization and SVR estimation
Derdelinckx et al. HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients
Atsumi et al. Antiphospholipid syndrome: pathogenesis
Yoshimura et al. Mechanisms for bone resorption induced by periodontal pathogens
Ning et al. Therapeutic activation of virus-specific resident memory T cells within the glioblastoma microenvironment
BR112014015654A2 (pt) método; sistema; e meio de armazenamento não transitório informático que armazena um conjunto de instruções executáveis por um processador
Jha et al. Lipid Droplets are active translation depots that respond to infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12826702

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12826702

Country of ref document: EP

Kind code of ref document: A2